Preliminary Assessment of Reference Region Quantification and Reduced Scanning Times for [18F]SynVesT-1 PET in Parkinson's Disease.

IF 2.2 4区 医学 Q3 BIOCHEMICAL RESEARCH METHODS
Molecular Imaging Pub Date : 2023-08-11 eCollection Date: 2023-01-01 DOI:10.1155/2023/1855985
Kelly Smart, Carme Uribe, Kimberly L Desmond, Sarah L Martin, Neil Vasdev, Antonio P Strafella
{"title":"Preliminary Assessment of Reference Region Quantification and Reduced Scanning Times for [<sup>18</sup>F]SynVesT-1 PET in Parkinson's Disease.","authors":"Kelly Smart, Carme Uribe, Kimberly L Desmond, Sarah L Martin, Neil Vasdev, Antonio P Strafella","doi":"10.1155/2023/1855985","DOIUrl":null,"url":null,"abstract":"<p><p>Synaptic density in the central nervous system can be measured <i>in vivo</i> using PET with [<sup>18</sup>F]SynVesT-1. While [<sup>18</sup>F]SynVesT-1 has been proven to be a powerful radiopharmaceutical for PET imaging of neurodegenerative disorders such as Parkinson's disease (PD), its currently validated acquisition and quantification protocols are invasive and technically challenging in these populations due to the arterial sampling and relatively long scanning times. The objectives of this work were to evaluate a noninvasive (reference tissue) quantification method for [<sup>18</sup>F]SynVesT-1 in PD patients and to determine the minimum scan time necessary for accurate quantification. [<sup>18</sup>F]SynVesT-1 PET scans were acquired in 5 patients with PD and 3 healthy control subjects for 120 min with arterial blood sampling. Quantification was performed using the one-tissue compartment model (1TCM) with arterial input function, as well as with the simplified reference tissue model (SRTM) to estimate binding potential (BP<sub>ND</sub>) using centrum semiovale (CS) as a reference region. The SRTM2 method was used with <i>k</i><sub>2</sub>' fixed to either a sample average value (0.037 min<sup>-1</sup>) or a value estimated first through coupled fitting across regions for each participant. Direct SRTM estimation and the Logan reference region graphical method were also evaluated. There were no significant group differences in CS volume, radiotracer uptake, or efflux (<i>ps</i> > 0.47). Each fitting method produced BP<sub>ND</sub> estimates in close agreement with those derived from the 1TCM (subject <i>R</i><sup>2</sup>s > 0.98, bias < 10%), with no difference in bias between the control and PD groups. With SRTM2, BP<sub>ND</sub> estimates from truncated scan data as short as 80 min produced values in excellent agreement with the data from the full 120 min scans (bias < 6%). While these are preliminary results from a small sample of patients with PD (<i>n</i> = 5), this work suggests that accurate synaptic density quantification may be performed without blood sampling and with scan time under 90 minutes. If further validated, these simplified procedures for [<sup>18</sup>F]SynVesT-1 PET quantification can facilitate its application as a clinical research imaging technology and allow for larger study samples and include a broader scope of patients including those with neurodegenerative diseases.</p>","PeriodicalId":18855,"journal":{"name":"Molecular Imaging","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445483/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/1855985","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}
引用次数: 0

Abstract

Synaptic density in the central nervous system can be measured in vivo using PET with [18F]SynVesT-1. While [18F]SynVesT-1 has been proven to be a powerful radiopharmaceutical for PET imaging of neurodegenerative disorders such as Parkinson's disease (PD), its currently validated acquisition and quantification protocols are invasive and technically challenging in these populations due to the arterial sampling and relatively long scanning times. The objectives of this work were to evaluate a noninvasive (reference tissue) quantification method for [18F]SynVesT-1 in PD patients and to determine the minimum scan time necessary for accurate quantification. [18F]SynVesT-1 PET scans were acquired in 5 patients with PD and 3 healthy control subjects for 120 min with arterial blood sampling. Quantification was performed using the one-tissue compartment model (1TCM) with arterial input function, as well as with the simplified reference tissue model (SRTM) to estimate binding potential (BPND) using centrum semiovale (CS) as a reference region. The SRTM2 method was used with k2' fixed to either a sample average value (0.037 min-1) or a value estimated first through coupled fitting across regions for each participant. Direct SRTM estimation and the Logan reference region graphical method were also evaluated. There were no significant group differences in CS volume, radiotracer uptake, or efflux (ps > 0.47). Each fitting method produced BPND estimates in close agreement with those derived from the 1TCM (subject R2s > 0.98, bias < 10%), with no difference in bias between the control and PD groups. With SRTM2, BPND estimates from truncated scan data as short as 80 min produced values in excellent agreement with the data from the full 120 min scans (bias < 6%). While these are preliminary results from a small sample of patients with PD (n = 5), this work suggests that accurate synaptic density quantification may be performed without blood sampling and with scan time under 90 minutes. If further validated, these simplified procedures for [18F]SynVesT-1 PET quantification can facilitate its application as a clinical research imaging technology and allow for larger study samples and include a broader scope of patients including those with neurodegenerative diseases.

Abstract Image

Abstract Image

Abstract Image

帕金森病[18F]SynVesT-1PET参考区域定量和缩短扫描时间的初步评估。
中枢神经系统中的突触密度可以使用PET和[18F]SynVesT-1在体内测量。虽然[18F]SynVesT-1已被证明是一种用于神经退行性疾病(如帕金森病)PET成像的强大放射性药物,但由于动脉采样和相对较长的扫描时间,其目前验证的采集和定量方案在这些人群中具有侵入性和技术挑战性。这项工作的目的是评估PD患者[18F]SynVesT-1的非侵入性(参考组织)定量方法,并确定准确定量所需的最短扫描时间。[18F]SynVesT-1 PET扫描在5名帕金森病患者和3名健康对照受试者中进行,共120例 min,动脉采血。使用具有动脉输入功能的单组织隔室模型(1TCM)以及简化参考组织模型(SRTM)进行量化,以使用半卵圆孔(CS)作为参考区域来估计结合电位(BPND)。使用SRTM2方法,k2’固定到样本平均值(0.037 min-1)或首先通过跨区域的耦合拟合为每个参与者估计的值。还评估了直接SRTM估计和Logan参考区域图解法。CS容量、放射性示踪剂摄取或外排没有显著的组间差异(ps>0.47)。每种拟合方法产生的BPND估计值与1TCM得出的值非常一致(受试者R2s>0.98,偏倚<10%),对照组和PD组之间的偏倚没有差异。使用SRTM2,BPND根据短至80的截断扫描数据进行估计 min生成的值与来自完整120的数据非常一致 最小扫描次数(偏差<6%)。虽然这些是来自PD患者小样本(n=5)的初步结果,但这项工作表明,可以在不进行血液采样和扫描时间低于90分钟的情况下进行准确的突触密度量化。如果进一步验证,[18F]SynVesT-1 PET定量的这些简化程序可以促进其作为临床研究成像技术的应用,并允许更大的研究样本,包括更广泛的患者,包括神经退行性疾病患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Imaging
Molecular Imaging Biochemistry, Genetics and Molecular Biology-Biotechnology
自引率
3.60%
发文量
21
期刊介绍: Molecular Imaging is a peer-reviewed, open access journal highlighting the breadth of molecular imaging research from basic science to preclinical studies to human applications. This serves both the scientific and clinical communities by disseminating novel results and concepts relevant to the biological study of normal and disease processes in both basic and translational studies ranging from mice to humans.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信